diethylnitrosamine has been researched along with albendazole in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amin, NA; Batiha, GE; El-Ahwany, E; El-Rous, MA; Elagamy, HI; Elewa, YHA; Elsergany, RN; Girgis, S; Gobba, NA; Hafez, AM; Kaddah, MMY; Kamal, I; Khodir, AE; Mahmoud, MH; Mourad, AAE; Nasr, M; Saad, AS; Saber, S; Shata, A | 1 |
1 other study(ies) available for diethylnitrosamine and albendazole
| Article | Year |
|---|---|
Albendazole-loaded cubosomes interrupt the ERK1/2-HIF-1α-p300/CREB axis in mice intoxicated with diethylnitrosamine: A new paradigm in drug repurposing for the inhibition of hepatocellular carcinoma progression.
Topics: Albendazole; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biological Availability; Carcinoma, Hepatocellular; Cyclic AMP Response Element-Binding Protein; Diethylnitrosamine; Disease Progression; E1A-Associated p300 Protein; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nanoparticles; Particle Size; Rats; Rats, Wistar | 2021 |